EX-10.20



 Exhibit 10.20 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS
OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]. 
  

											
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	 	1. CONTRACT ID CODE	 	PAGE OF PAGES
	 		 	1	 	1


													
	2. AMENDMENT/MODIFICATION NO.  	 	3. EFFECTIVE DATE	 	4. REQUISITION/PURCHASE REQ. NO.  	 	5 PROJECT NO, (If applicable)    
	 0014
  
	 	 	 	See Block 16C	 	 	 	 	 	 
	5. ISSUED BY	 	CODE  	 	ASPR-BARDA	 	7. ADMINISTERED BY (If other than Item 6)	 	ASPR-BARDA02
	  
 ASPR-BARDA

200 Independence Ave., S.W.
 Room 640-G

Washington DC 20201
  
	 		 	  
 ASPR-BARDA

330 Independence Ave, SW, Rm G640
 Washington DC
20201
	 	
	 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county,
State and ZIP code
  
 PFENEX, INC
1358378
 FENEX BIOPHARMACEUTICALS, INC.
 10790
ROSELLE ST
 SAN DIEGO CA 921211718
	 	  
 (x)
	 	 9A. AMENDMENT OF SOLICITATION NO.

 

	 	 	 	 9B. DATED (SEE ITEM 11)

 
  
	 	 	 	 
	 	x  	 	10A. MODIFICATION OF CONTRACT/ORDER NO.
	 		 	 HHSO100201000045C
  
	 		 	
	 		 	10B. DATED (SEE ITEM 13)
	 CODE 1358378

 
	 	 	 	 FACILITY CODE
  
	 		 	 07/30/2010
  
	 		 	


					
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	The above numbered solicitation is amended as set forth in Item 14. The hour end date specified for receipt of Offers
                     is extended
                     is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the
solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning          copies of the amendment; (b) By acknowledging receipt of this Amendment on
each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO
THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the
solicitation and this amendment, and is received prior to the opening hour and date specified.
	12. ACCOUNTING AND APPROPRIATION. DATA (if required)
	See Schedule
	13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
	 CHECK

ONE
	 	A.	  	THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
	 	 	
	 	 	 	  	     
		 	B.	  	THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR
43.103(b).
	X	 	 	  	 
		 	C.	  	THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
		 	    	  	
	 	 	D.	  	OTHER (Specify type of modification and authority)
	 	 	    	  	 
	  

E. IMPORTANT:    Contractor          is not X is required to sign
this document and return 1 copies to the issuing office
  

	 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject
matter where feasible.)
 Tax ID Number:    27-1356759

DUNS Number:    013603710
 A. The
purpose of this modification is to transfer the inventory on the attached list from this expired contract HHS0100201000045C to active contract HHSO100201500011C.
  

SEE ATTACHED
  

B. This is a bilateral administrative no-cost modification. The total contract amount and all other terms and conditions remain the same.

Period of Performance: 07/30/2010 to 08/31/2015
 Except as
provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.



							
	15A. NAME AND TITLE OF SIGNER (Type or print)	  	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
	Patrick Lucy - Chief Business Officer	  		  	THOMAS P. HASTINGS	  	
	15B. CONTRACTOR/OFFEROR	  	15C. DATE SIGNED	  	16B: UNITED STATES OF AMERICA	  	16C. DATE SIGNED
	  
 /s/ Patrick Lucy

(Signature of person authorized to sign)
	  	  
 10/19/15
	  	  
 /s/ Thomas P.
Hastings
 (Signature of Contracting Officer)
	  	  
 10/20/15


  

			
	NSN 7540-01-152-8070	  	STANDARD FORM 30 (REV. 10-83)
	Previous edition unusable	  	Prescribed by GSA
		  	FAR (48 CFR) 53.243


  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 








 



 
  

	 	1.	Inventory 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	Pfenex Confidential	  	Page 1 of 6









 [***] 
  

																																							
	 item number
	  	 Description
	  	Concentration	 	 	Volume	 	 	Container	 	 	Lot #	 	 	Date of
Manuf.	 	 	Storage	 	 	Amount	 	 	Inventory
date	 	 	Storage
location	 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 [***] 

[***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  

			
	Pfenex Confidential	  	Page 2 of 6









 [***] 
  

																																							
	 Sentry item
number
	  	 Description
	  	Concentration	 	 	Volume	 	 	Container	 	 	Lot #	 	 	Date of
Manuf.	 	 	Storage	 	 	# Vials	 	 	Inventory
date	 	 	Storage
location	 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 [***] 
 [***] 

[***] 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  

			
	Pfenex Confidential	  	Page 3 of 6









 [***] 
  

																	
	 Reagent/Materials Name
	  	 mrPA lot/DOM
	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition
(°C)	 	 	Date	 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 [***] 
 [***] 

 

																	
	 Reagent/Materials Name
	  	 mrPA lot
	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition
(°C)	 	 	Date	 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	Pfenex Confidential	  	Page 4 of 6









 [***] 
  

																	
	 Reagent/Materials Name
	  	 Lot
	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition (°C)	 	 	Date	 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 [***] 
  

																	
	 Reagent/Materials Name
	  	 Source
	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition (°C)	 	 	Date	 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 [***] 
  

																	
	 Reagent/Materials Name
	  	 Strain
	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition (°C)	 	 	Date	 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	Pfenex Confidential	  	Page 5 of 6










																	
	 Reagent/Materials Name
	  	 	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition (°C)	 	 	Date	 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
						
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 [***] 
  

																	
	 Reagent/Materials Name
	  	 	  	 Description
	  	Amount left
(units)	 	 	Storage
Condition (°C)	 	 	Date	 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 [***]
	  	[***]	  	[***]	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  
 [***] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	Pfenex Confidential	  	Page 6 of 6